Grant Life Sciences enters into Memorandum of Understanding (MOU) with U.S. State Department's 'Bio-Industry Initiative' (BII) 1/19/06
MURRAY, Utah, Jan 19, 2006 (BUSINESS WIRE) -- 'BII' designed to foster medical and other biological R&D in the former Soviet Union by converting former biowarfare scientists to productive peacetime activities
Grant Life Sciences Inc. (OTC Bulletin Board: GLIF) announced today the signing of a Memorandum of Understanding (MOU) with Dr. Peter Sveshnikov and Dr. Vsevolod Kiselev of the Russian Republic, for the in-licensing of certain of their technologies that are highly complementary to Grants' antibody-based test for detecting cervical cancer. The Sveshnikov/Kiselev technology comes to Grant from the U.S. State Department through its Bio-Industry Initiative (BII) program. The BII is designed to foster medical and other biological research and development in the former Soviet Union by converting former biowarfare scientists to productive peacetime activities.
Sveshnikov/Kiselev have developed an Enzyme-Linked Immunosorbent Assay (ELISA) to detect specific cancer-causing proteins from the human papillomavirus (HPV) -- the obligate cause of cervical cancer -- in the cervical mucous and cells (which make up liquid-based pap samples). The test utilizes certain monoclonal antibodies against these cancer-causing HPV proteins for detection. Thus far, the test is designed to detect cancer-causing proteins from HPV types 16 and 18 which, collectively, are responsible for most cervical disease. This type-specific antigen test, once fully validated and expanded to include additional types of HPV associated with cervical dysplasia and cancer, would be a very synergistic and complementary test to existing Pap technology. It will provide for very low-cost HPV testing as currently performed in Western countries, without the need for additional cervical specimens beyond what is now taken. In addition, large capital outlays would not be required, since most laboratories can readily do ELISA testing.
Sveshnidov/Kiselev have already tested their technology with 1000 Russian samples to confirm the potential of this technology. Grant will be further validating with more specimens from Russia and via the many cervical specimens obtained in the United States under its Institutional Review Board (IRB) approval in controlled clinical settings.
"Together, when validated, Grant will have two complementary cervical dysplasia or cancer diagnostic tests that will work on blood serum or cervical mucous and cells," said Dr. Hun-Chi Lin, President and Chief Scientist at Grant. "A blood-based test is eminently suitable for the 1.7 billion women worldwide who currently are not tested by Pap smear cytology. This inadequacy results in over 300,000 deaths per year. Meanwhile, a test employing cervical mucous or cells is readily fitting for Western medical venues, and has the potential of reducing costs dramatically when compared against those for current HPV DNA-testing. Furthermore, it could significantly reduce expenditures for follow-up referral procedures that turn out to be overwhelmingly negative, with billions of dollars per year in unnecessary medical expenses saved as a consequence."
Posted by OO7 on :
should be a runner this A.M.
Posted by sunny on :
Have my eyes on this one today.
Posted by MB on :
LII jumping on this one..looks like it will open at .03
Posted by MB on :
Dropped back to 26 and bid is building I might get in here for a little ride...
Posted by MB on :
265x27
Posted by MB on :
27x275
Posted by firefighterswct on :
Ive watch this stock plenty of times it will bounce around here for a while and should line its self up for an EOD run, something to watch for
Posted by MB on :
this one got me I will hold and try to get some $ back Fri or Mon.
Posted by lukin4winners on :
GLIF chart looks good for a move upward if the mm's will let it go... they must need shares.
Posted by MovingUp on :
Does anyone have a guess as to what this might run to?
![[Frown]](frown.gif)
I will hold and try to get some $ back Fri or Mon.